Table 1

Results of the quantitative analysis (n=determinations)

Biomarker	Grouping by technique type	Determinations
Biomarker	Grouping by technique type	n	(%)
	PCR	2631	94.4
	Sequencing	110	3.90
	Outsourced	45	1.60
	Total EGFR determinations	2786	100
ALK	IHC—clone D5F3	1990	80.70
	IHC—clone 54A	210	8.50
	FISH	320	13.00
	Other (PCR)	3	0.10
	Total ALK determinations	2523	102.3*
ROS1	IHC—clone D4D6	1069	55.70
	IHC—clone SP384	0	–
	FISH	846	44.10
	Outsourced	16	0.80
	Total ROS1 determinations	1931	100.7*
PD-L1	IHC—clone 22C3	782	43.50
	IHC—clone SP263	559	31.10
	IHC—clone 28–8	393	21.80
	IHC—clone E1L3N	31	1.70
	Outsourced	34	1.90
	Total PD-L1 determinations	1799	100.00

*IHC and FISH are mutually non-exclusive. 3,4% and 2% of positive results obtained by IHC screening and confirmed by FISH for ALK and ROS1, respectively.
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridisation; IHC, immunohistochemistry; PD-L1, programmed death ligand-1; ROS1, c-ros oncogene 1.